Cause of Pigment Dispersion Syndrome

NCT ID: NCT00005919

Last Updated: 2008-03-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-06-30

Study Completion Date

2003-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn how pigment is released from the iris (the colored part of the eye) in patients with pigment dispersion syndrome. It will do this by examining the response of the pupil (the central opening of the iris) to a flash of light to determine what is happening in the iris to cause release of the pigment.

In pigment dispersion syndrome, pigment released from the iris is deposited in other parts of the eye, including the trabecular meshwork-a filter-like tissue in the front of the eye. Aqueous fluid (fluid continuously produced by the eye) normally flows out of the eye through the trabecular meshwork. In some patients, the pigment deposits may block tiny holes in the meshwork, preventing the fluid from flowing out. This can cause an increase in eye pressure that may lead to glaucoma and some loss of vision. Understanding how pigment is released from the iris may help predict the course of pigment dispersion syndrome and identify which patients will likely develop increased eye pressure.

Patients with pigment dispersion syndrome and normal volunteers may be eligible for this study. All participants will have the following procedures, which will be completed in two clinic visits:

First visit

1. Examination of the front of the eyes, including the cornea, iris and lens.
2. Vision testing and measurements of visual field and eye pressure.
3. Examination of the trabecular meshwork. For this test, a contact lens is placed on the eye after the eye has been numbed with anesthetic drops.

Second visit

1. Refraction (dilation of the pupils with drops) and examination of the back of the eyes, including the optic nerve.
2. Reaction of the pupils to low-level infrared light (pupillography). During this 15-minute test, the patient or volunteer wears a lightweight headband with two small cameras mounted on it. The cameras-one which views the eye and the other the subject's field of view-record pupil dilation and position.

The test results in patients with pigment dispersion syndrome will be compared with those in normal volunteers. Patients will be followed every 6 months (or more often, if medically indicated) during the 3-year study to determine changes in eye pressure or visual field. Volunteers will be asked to return about once a year for 3 years for repeat pupillography.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to conduct a comprehensive ophthalmologic evaluation and comparison of two types of patients and to compare them to normal controls. The two types of patients are those with pigment dispersion (PDS) with normal intraocular pressure (IOP) and those with PDS and elevated IOP. The hypothesis to be tested is that a developmental abnormality of the iris pigment epithelium (IPE) and the dilator muscle is the fundamental defect responsible for the pigment dispersion. This defect may involve other structures of the eye such as the ciliary and retinal pigment epithelium. The results of pupillography in PDS with or without elevated IOP and asymmetric PDS (one eye versus fellow eye) will be the outcome parameters.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma Healthy Pigment Dispersion Syndrome

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients entering the study must have black pigment deposition on the trabecular meshwork at the site of Schlemm's canal equal to or greater than 2-plus on the goniophotographic scale of 1 to 5 plus.

Although this condition is rare amongst African-Americans, every effort will be made to recruit such individuals.

Exclusion Criteria

Patients with exfoliation syndrome, uveitis, trauma, pigment dispersion with posterior chamber intra-ocular lens, pigmented tumors, primary open-angle glaucoma, other conditions with associated pigment dispersion such as acute angle-closure glaucoma, ocular hemorrhage, Horner's syndrome.

In addition, normal volunteers will be recruited as controls. They will be free of any eye disease and be matched for age, sex and degree of myopia.
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Eye Institute (NEI)

NIH

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Eye Institute (NEI)

Bethesda, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Ferris FL 3rd, Sperduto RD. Standardized illumination for visual acuity testing in clinical research. Am J Ophthalmol. 1982 Jul;94(1):97-8. doi: 10.1016/0002-9394(82)90198-2. No abstract available.

Reference Type BACKGROUND
PMID: 7091290 (View on PubMed)

Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982 Jul;94(1):91-6.

Reference Type BACKGROUND
PMID: 7091289 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

00-EI-0155

Identifier Type: -

Identifier Source: secondary_id

000155

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.